Clinical trials are how new treatments and improved outcomes are developed in health care. Highlands Oncology has been participating in clinical trials for over 26 years. Our Research Department operates numerous clinical trials in both oncology and hematology. New experimental medications, or different ways to use existing medications, are compared to the currently available treatments in order to advance cancer care for patients around the world.
Each clinical trial has certain criteria that must be met to participate. These guidelines help protect the safety of each patient. There are four phases of clinical trial development:
- Phase I – Assessing medication dose and safety
- Phase II – Further assessing safety and efficacy
- Phase III – Comparison to currently available medications
- Phase IV – Further study of already FDA-approved medications
Phase I clinical trials provide new, novel approaches for the treatment of cancer. Highlands Oncology has the privilege of being the only community based Phase I oncology clinical trial center in the state of Arkansas. Cancer research is always evolving and new treatments emerge every year. Highlands Oncology stays at the cutting edge of technology with help from the Research Department and clinical trials.
We strive to provide as many options as possible for the treatment of cancer. Only you and your doctor can decide if a clinical trial is right for you. If you are interested in participating in a clinical trial, please review our list of currently enrolling clinical trials. For further information on clinical trials, please visit http://www.clinicaltrials.gov.
For questions or more information, please contact the Research Department:
- By email: research@hogonc.com
- By phone: 479-872-8130
- Contact Highlands Oncology: 479-587-1700
| Stemline STML-ELA-0222 – A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer | BREAST | 07/27/2023 | View Here |
| Stemline STML-ELA-0322 – ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer: An Open-Label Multicenter Phase 2 Study (ELCIN) | BREAST | 07/26/2023 | View Here |
| AstraZeneca D926NC00001 Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin for First-Line Treatment of Patients With Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR) | LUNG – Non Small Cell Cancer (NSCLC) | 05/25/2023 | View Here |
| AstraZeneca D926XC00001 – A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03) | BREAST | 02/15/2023 | View Here |
| Arvinas ARV-471-BC-201: This is a Phase 2, open-label, randomized, non-comparative proof of concept study of ARV-471 or anastrozole in participants with ER+/HER2- breast cancer amenable to definitive surgical resection. The main goal of this study is to evaluate the biological activity of ARV-471 and anastrozole, respectively. |
BREAST | 02/15/2023 | View Here |
| Merck MK1026-003: A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies | OTHER | 02/02/2023 | View Here |
| AstraZeneca D967RC00001: A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed by THP Compared to ddAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11) | BREAST | 01/26/2023 | View Here |
| Daiichi Sankyo DS7300-127: A Phase 2, Multicenter, Randomized, Open-label Study of DS-7300a, a B7-H3 Antibody Drug Conjugate (ADC), in Subjects With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) | LUNG | 01/11/2023 | View Here |
| Imugene CF33-hNIS-002: This is an open-label, dose-escalation, multi-center phase I study evaluating the safety of CF33-hNIS (hNIS – human sodium iodide symporter) administered via two routes of administration, intratumoral (IT) or intravenous (IV), either as a monotherapy or in combination with pembrolizumab in patients with metastatic or advanced solid tumors. | Solid Tumors | 01/05/2023 | View Here |
| Freenome FRNM-008: The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening | OTHER | 12/27/2022 | View Here |
| Shanghai Henlius Biotech HLX10-005-SCLC301-E: A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | LUNG – Small Cell Cancer (SCLC) | 12/12/2022 | View Here |
| Eli Lilly J2J-MC-JZLH: EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence | BREAST | 11/22/2022 | View Here |
| Pfizer C4901001: A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | Solid Tumors | 11/11/2022 | View Here |
| OncoC4 ONC-392-001: Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001) | OTHER | 10/28/2022 | View Here |
| Revolution Medicines RMC-6291-001: Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | LUNG – Non Small Cell Cancer (NSCLC) | 10/24/2022 | View Here |
| Bristol-Myers Squibb CA027-002: A Phase 1/2 Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers | MELANOMA | 10/24/2022 | View Here |
| Sarah Cannon BRE-354: A Phase II Study of U3-1402 in Patients With Metastatic Breast Cancer | BREAST | 10/21/2022 | View Here |
| Seagen Inc., SGN35-033: A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies After Progression on Prior PD-1 Inhibitor Treatment | MELANOMA | 10/17/2022 | View Here |
| Ascentage Pharma APG-5918XG101: A Phase I Study of Safety, Pharmacokinetic and Efficacy of Orally Administered APG-5918 in Patients With Advanced Solid Tumors or Hematologic Malignancies |
OTHER | 10/13/2022 | View Here |
| EQRx International EQ 143-301: A Randomized, Three-Arm, Open-Label Phase 3b Clinical Trial of Aumolertinib, Versus Aumolertinib With Chemotherapy, Versus Osimertinib for Patients With Metastatic NSCLC and an EGFR Mutation | LUNG – Non Small Cell Cancer (NSCLC) | 08/09/2022 | View Here |
| Guardant 02-MX-002 SHIELD – Screening for High Frequency Malignant Disease (SHIELD) | LUNG | 08/08/2022 | View Here |
| iTEOS A2A-005: Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer | LUNG – Non Small Cell Cancer (NSCLC) | 08/08/2022 | View Here |
| Eli Lilly I3Y-MC-JPEG: CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer | PROSTATE | 07/26/2022 | View Here |
| Novartis CLEE011A2412B: A Post-trial Access Roll-over Study to Allow Access to Ribociclib (LEE011) for Patients Who Are on Ribociclib Treatment in Novartis-sponsored Study | BREAST | 07/07/2022 | View Here |
| Daiichi Sankyo: U31402-A-U301- A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy | LUNG – Non Small Cell Cancer (NSCLC) | 06/08/2022 | View Here |
| Takeda TAK573-1501: A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma | MULTIPLE MYELOMA | 06/03/2022 | View Here |
| Bristol-Myers Squibb: CA224-123 – A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer (RELATIVITY-123) | COLORECTAL | 06/03/2022 | View Here |
| Pfizer C4761001- A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI TUMOR ACTIVITY OF PF-07799933 (ARRY-440) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS | MELANOMA | 05/26/2022 | View Here |
| Pfizer: C4201002 – A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE-FINDING, PHARMACOKINETIC, SAFETY AND TOLERABILITY STUDY OF PF 07265807 IN PARTICIPANTS WITH SELECTED ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES. | Solid Tumors | 05/19/2022 | View Here |
| Navire Pharma Inc., Nav-1004: A Phase 1 Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Combination With the Programmed Death Receptor-1 Blocking Antibody Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation | LUNG – Non Small Cell Cancer (NSCLC) | 05/16/2022 | View Here |
| Gritstone Bio, Inc. GO-010: A Study of a Personalized Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer. | COLORECTAL | 04/18/2022 | View Here |
| Eli Lilly I3Y-MC-JPEF: A Phase 3: Randomized, Double Blind: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Advanced or Metastatic Breast, HR+, HER2-, following progression on a CDK 4/6 Inhibitor and Endocrine Therapy. | BREAST | 01/10/2022 | View Here |
| AstraZeneca D967UC00001: Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09) | BREAST | 01/03/2022 | View Here |
| AstraZeneca D8532C00001 (SERENA-4): A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease. | BREAST | 12/06/2021 | View Here |
| Mirati Therapeutics Inc. 849-007: Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab for NSCLC With KRAS G12C Mutation KRYSTAL-7. | LUNG – Non Small Cell Cancer (NSCLC) | 11/02/2021 | View Here |
| Pfizer C4401001: A Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. | Solid Tumors | 09/30/2021 | View Here |
| Seattle Genetics SGNS40-002: An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Subjects with Advance Malignancies | OTHER | 09/16/2021 | View Here |
| Immunomedics IMMU-132-11: A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors | Solid Tumors | 06/16/2021 | View Here |
| Vaccinex VX15/2503-12: A Phase 1b/2 Study of the Combination of Pepinemab and Pembrolizumab in Patients with Advanced, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. | HEAD/NECK | 04/29/2021 | View Here |
| TG Therapeutics TG-1801-102: “A Phase 1b Multi-cohort Study of TG-1801 Alone or in Combination with Ublituximab in Subjects with B-Cell Lymphoma or Chronic Lymphocytic Leukemia” | LEUKEMIA – Chronic Lymphocytic | 04/07/2021 | View Here |
| Hutchison 2020-013-00US3: An Open-Label, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Fruquintinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors | OTHER | 03/26/2021 | View Here |
| Mirati Therapeutics 849-010: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy | COLORECTAL | 03/15/2021 | View Here |
| AbbVie M20-124: A Phase 1, Multi-center, Open Label First-in-Human Study with ABBV-CLS-579 Alone and in Combination with Anti-PD-1 in Subjects with Locally Advanced or Metastatic Tumors | Solid Tumors | 03/01/2021 | View Here |
| Abbvie M20-178: A Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis (TRANSFORM-2). | Myelofibrosis | 10/02/2020 | View Here |
| AbbVie M19-037: A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects with Locally Advanced or Metastatic Solid Tumors |
OTHER | 07/14/2020 | View Here |
| Ultimovacs UV1-202: A Randomized Phase II, Open-Label, Active-Controlled, Multicenter Study Investigating the Efficacy and Safety of UV1 Vaccination in Combination with Nivolumab and Ipilimumab as First-Line Treatment of Patients with Unresectable or Metastatic Melanoma |
MELANOMA | 05/28/2020 | View Here |
| AbbVie M14-239: Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer |
LUNG – Non Small Cell Cancer (NSCLC) | 03/11/2020 | View Here |
| AbbVie M16-573: A Phase I First-in-Human Study with ABBV-155 Alone and in Combination with Taxane Therapy in Adults with Relapsed and/or Refractory Solid Tumors |
OTHER | 02/06/2020 | View Here |
| Ascentage Pharma APG-115-US-002: A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors | OTHER | 09/10/2019 | View Here |
| Southwest Oncology Group (SWOG) S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors | OTHER | 04/10/2018 | View Here |
